导管消融与药物心率控制对房颤合并收缩功能不全患者的对比:CAMERA-MRI研究
CAMERA-MRI多中心随机试验纳入68例持续性房颤合并特发性心肌病(LVEF≤45%)患者,随机接受导管消融或药物心率控制。6个月时消融组LVEF绝对改善18±13%,药物组4.4±13%(p<0.0001);LVEF正常化率分别为58%和9%(p=0.0002)。无延迟钆增强者消融后改善更显著。
要点
- 导管消融恢复窦律可显著改善特发性心肌病合并房颤患者的LVEF。
- 无心室纤维化(CMR无延迟钆增强)者LVEF改善和正常化率更高。
- 结果挑战了房颤合并LVSD以心率控制为主的传统策略。
核心结论
- 房颤是LVSD一个被低估的可逆原因,即使心率控制充分。
- 导管消融恢复窦律可显著改善心室功能,尤其在CMR无心室纤维化时。
- 该结果挑战了房颤合并LVSD以心率控制为适当策略的现行治疗范式。
研究设计与样本
- 随机前优化心率控制并完成心脏磁共振评估LVEF和延迟钆增强,随机分配至导管消融或继续药物心率控制。
- 导管消融包括肺静脉隔离和后壁隔离;消融后采用植入式 loop recorder 评估房颤负荷,系列 Holter 评估药物心率控制充分性。
- 主要终点为6个月时重复CMR测定的LVEF变化。
主要发现
- 消融后6个月平均房颤负荷为1.6±5.0%。
- 意向性治疗分析中,消融组LVEF绝对改善18±13%,药物心率控制组4.4±13%(p<0.0001)。
- 消融组58%患者LVEF正常化(LVEF≥50%),药物组9%(p=0.0002)。
- 消融患者中,无延迟钆增强者LVEF绝对改善更显著(10.7%;p=0.0069),6个月正常化率73% vs 29%(p=0.0093)。
关键数值与推荐
- 入组标准:持续性房颤合并特发性心肌病,LVEF≤45%。
- 主要终点:6个月时重复CMR测定的LVEF变化。
- LVEF正常化定义为LVEF≥50%。
临床怎么用
- 对持续性房颤合并特发性LVSD且心率控制充分的患者,可考虑导管消融以恢复窦律并改善心室功能。
- CMR延迟钆增强可用于识别可能从消融中获益更大的患者(无纤维化者改善更显著)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation (AF) and left ventricular systolic dysfunction (LVSD) frequently co-exist despite adequate rate control. Existing randomized studies of AF and LVSD of varying etiologies have reported modest benefits with a rhythm control strategy. OBJECTIVES: The goal of this study was to determine whether catheter ablation (CA) for AF could improve LVSD compared with medical rate control (MRC) where the etiology of the LVSD was unexplained, apart from the presence of AF. METHODS: This multicenter, randomized clinical trial enrolled patients with persistent AF and idiopathic cardiomyopathy (left ventricular ejection fraction [LVEF] ≤45%). After optimization of rate control, patients underwent cardiac magnetic resonance (CMR) to assess LVEF and late gadolinium enhancement, indicative of ventricular fibrosis, before randomization to either CA or ongoing MRC. CA included pulmonary vein isolation and posterior wall isolation. AF burden post-CA was assessed by using an implanted loop recorder, and adequacy of MRC was assessed by using serial Holter monitoring. The primary endpoint was change in LVEF on repeat CMR at 6 months. RESULTS: A total of 301 patients were screened; 68 patients were enrolled between November 2013 and October 2016 and randomized with 33 in each arm (accounting for 2 dropouts). The average AF burden post-CA was 1.6 ± 5.0% at 6 months. In the intention-to-treat analysis, absolute LVEF improved by 18 ± 13% in the CA group compared with 4.4 ± 13% in the MRC group (p < 0.0001) and normalized (LVEF ≥50%) in 58% versus 9% (p = 0.0002). In those undergoing CA, the absence of late gadolinium enhancement predicted greater improvements in absolute LVEF (10.7%; p = 0.0069) and normalization at 6 months (73% vs. 29%; p = 0.0093). CONCLUSIONS: AF is an underappreciated reversible cause of LVSD in this population despite adequate rate control. The restoration of sinus rhythm with CA results in significant improvements in ventricular function, particularly in the absence of ventricular fibrosis on CMR. This outcome challenges the current treatment paradigm that rate control is the appropriate strategy in patients with AF and LVSD. (Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction [CAMERA-MRI]; ACTRN12613000880741).
引用
- Prabhu S, Taylor AJ, Costello BT, et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. J Am Coll Cardiol. 2017. PMID: 28855115. doi:10.1016/j.jacc.2017.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。